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Abstract
The BRAF mutation occurs commonly in papillary thyroid carcinoma (PTC).
Previous investigations of its utility to predict recurrence-free survival (RFS)
and disease-specific survival (DSS) have reported conflicting results and its role
remains unclear. The purpose of this retrospective study was to determine the
incidence of the BRAF mutation and analyze its relationship to clinicopatho-
logic risk factors and long-term outcomes in the largest, single-institution
American cohort to date. BRAF mutational status was determined in 508 PTC
patients using RFLP analysis. The relationships between BRAF mutation status,
patient and tumor characteristics, RFS, and DSS were analyzed. The BRAF
mutation was present in 67% of patients. On multivariate analysis, presence of
the mutation predicted only for capsular invasion (HR, 1.7; 95% CI, 1.1–2.6),
cervical lymph node involvement (HR, 1.7; 95% CI, 1.1–2.7), and classic papil-
lary histology (HR, 1.8; 95% CI 1.1–2.9). There was no significant relationship
between the BRAF mutation and RFS or DSS, an observation that was consis-
tent across univariate, multivariate, and Kaplan–Meier analyses. This is the
most extensive study to date in the United States to demonstrate that BRAF
mutation is of no predictive value for recurrence or survival in PTC. We found
correlations of BRAF status and several clinicopathologic characteristics of high-
risk disease, but limited evidence that the mutation correlates with more exten-
sive or aggressive disease. This analysis suggests that BRAF is minimally prog-
nostic in PTC. However, prevalence of the BRAF mutation is 70% in the
general population, providing the opportunity for targeted therapy.
Introduction
Papillary thyroid carcinoma (PTC) is the most common
endocrine malignancy [1]. The incidence of PTC has
increased over the past several decades and now com-
prises 88% of all thyroid carcinomas [2–5]. The course is
fairly indolent and treatment is curative, typically involv-
ing surgery followed by radioactive Iodine131 (RAI)
administration [2, 6]. However, a select patient popula-
tion displays a more aggressive phenotype marked by
disease recurrence or death due to thyroid cancer [2].
Efforts have been made to identify patients at risk and to
develop methods to distinguish markers, such as somatic
mutations, that might predict for good versus poor prog-
nosis.
One such mutation that has been extensively studied is
the BRAF gene mutation. The majority of these mutations
involve a transversion from T to A at nucleotide 1799,
leading to a valine to glutamic acid change in codon 600.
This results in the BRAFV600E mutation which is the most
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common mutation in PTC. It occurs in about 70% of
patients [7–9]. Additional activating mutations in V600,
such as V600K and V600D are well described but account
for only a minority of cases [10–12]. Their exact inci-
dence in a thyroid cancer-specific setting is not estab-
lished. Multiple publications have reported associations
between BRAF V600 mutations (hereafter referred to col-
lectively as BRAF) and poor prognosis [13–16]. It has
been reported that the BRAF mutation correlates with
increased disease recurrence and disease-specific mortality
[9, 17–19]. However, several recent studies have failed to
corroborate these findings, leaving the overall significance
of the BRAF mutation unclear [20–24].
Much of the literature investigating the role of the
BRAF mutation in outcomes of PTC has been limited by
the shortcomings of meta-analysis or has been otherwise
limited by low patient numbers or short follow-up. In a
disease such as PTC, where negative events such as recur-
rence and disease-related mortality are rare and often
occur late, a large patient cohort and extended follow-up
time are critical to the strength of analysis. As such, while
some groups have suggested that PTC patients should be
routinely tested for the BRAF mutation in order to guide
therapy, the prognostic utility of the BRAF mutation as a
predictor of recurrence or mortality has not been strongly
established [25, 26].
This retrospective study, with the largest cohort of
patients and longest follow-up time of any single institu-
tion in the United States to date, analyzed the relation-
ship between the BRAF mutation and PTC. Clinical and
pathological outcomes, including disease recurrence and
disease-specific mortality, and BRAF mutational status
were analyzed for possible correlations.
Materials and Methods
Patient identification and clinicopathologic
data collection
This retrospective study was approved by the Human
Research Protection Office at our institution, including
retrospective chart review (protocol number 201010705)
with waiver of consent. Records of 1712 patients with
thyroid cancer who were referred to the department at
our facility from 1974 to 2009 were queried. The data set
was interrogated for patients with thyroid carcinoma of
follicular cell origin who met the following criteria:
underwent either partial or total thyroidectomy, received
follow-up care, had classic papillary or follicular variant
histologic subtypes of PTC, and had available tumor spec-
imens. A total of 508 patients met criteria. Thyroid tumor
specimens were obtained from an archived bank of for-
malin-fixed, paraffin-embedded (FFPE) thyroid tissue.
Anaplastic and undifferentiated thyroid carcinomas were
excluded from the study. Data abstracted from patient
records included histological subtype, treatment records,
and clinicopathologic outcomes. Review of records indi-
cated that none of these individuals had any history of
therapeutic radiation exposure. BRAF mutational status
was determined after surgical and medical treatments of
all patients were concluded and did not affect treatment
decisions.
PTC histological classification
Hematoxylin and eosin stained slides were examined by
study pathologists to identify areas with classic character-
istics of PTC, including papillary architecture, typical
PTC nuclei (enlarged, overlapping, irregular, ground-glass
empty nuclei with nuclear grooves), psammoma bodies,
and stromal reaction [27]. Histologically, the 508 cases
were comprised of classical (n = 383) and follicular vari-
ant (n = 131) subtypes of PTC, classified using standard
criteria [27–29]. Areas of carcinoma were marked on the
glass slides to guide collection of tissue cores from the
corresponding FFPE tumor blocks of the case.
DNA extraction and BRAF mutation analysis
Two tissue cores of 1 mm diameter were extracted from
the areas of tumor by means of disposable biopsy
punches with plungers (Miltex, York, PA). Samples were
incubated in xylene for three minutes at 50°C; xylene
aspiration was followed by two washes with 100% etha-
nol. Subsequently, samples were incubated for 48 h with
0.5 mg/mL proteinase K (Quiagen, Germantown, MD),
with a mid-interval addition of 0.5 mg/mL proteinase K.
DNA was extracted from each sample via a commercial
kit (Puregene, Minneapolis, MN) according to the man-
ufacturer’s instructions. Following extraction, DNA was
stored at 4°C. Polymerase chain reaction (PCR) was uti-
lized to amplify the 215 base pair (bp) BRAF exon 15,
using previously published primers and Platinum Taq
DNA Polymerase (Invitrogen, Carlsbad, CA), according
to the manufacturer’s instructions. Primers (Invitrogen)
were: BRAF exon 15F (forward): 50-TCATAATGCTTGC
TCTGATAGGA-30, BRAF exon 15R (reverse): 50-GGCC
AAAAATTTAATCAGTGGA-30. PCR conditions consisted
of 35 cycles with 1 min of denaturation at 94°C, 1 min of
annealing at 51°C, and 1 min of extension at 72°C [30].
Samples were then subjected to restriction fragment
length polymorphism (RFLP) analysis by the enzyme
TspRI (Invitrogen), using the buffer conditions recom-
mended by the manufacturer. TspRI cuts the wild-type
215 bp amplification product into two fragments of 120
and 95 bp. Oncogenic BRAF V600 point mutations
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disrupt the restriction site, thereby blocking the cleavage
of the amplification product. After the restriction digest,
the DNA bands were resolved by agarose gel electropho-
resis and visualized by ethidium bromide staining.
Assay validation
Restriction fragment length polymorphism (RFLP) analysis
has been used by numerous other laboratories to evaluate
BRAF exon 15 [30–33]. We performed several steps to vali-
date the assay for use in our own laboratory. To establish
test accuracy, we compared our results with those of direct
DNA sequencing by a commercial clinical reference labora-
tory (GenPath, Elmwood Park, NJ). For 40 cases of PTC
diagnosed between 2009 and 2011 (20 cases with and 20
cases without a BRAF V600 mutation) there was 100% con-
cordance between our test and the outside laboratory. These
40 test cases did not overlap with the 508 cases presented
here, due to the relative paucity of follow-up data for such
recent cases. To establish the reproducibility of the assay, all
40 cases in the validation set were tested three times (in a
blinded fashion); there was 100% concordance between test
runs. To establish the sensitivity of the test, PCR-amplified
DNA from known BRAF mutation samples (at 100 nmol/
ml) was diluted into BRAF-negative DNA (also at
100 nmol/mL); dilution ratios were 1:0, 1:1, 1:2, 1:3, 1:5,
1:10, and 1:20 of BRAF mutation positive to negative. These
dilutions were then subjected to restriction enzyme analysis
and gel electrophoresis, as previously described. The mutant
allele could be reproducibly identified when present at an
allele frequency of at least 10% in the sample.
Treatment and follow-up
Most patients underwent total thyroidectomy (97%), 3%
had a lobectomy or partial resection, and 0.6% of patients
had a thyroid biopsy, only. Surgery for metastatic lymph
nodes was performed in 57% of patients, consisting of selec-
tive nodal dissection in 46% and modified radical neck dis-
section in 11%. The remaining 43% had no surgical removal
of neck lymph nodes. Postoperative 131I was administered to
94% of patients. Nine additional patients were treated with
131I after recurrence. The administered activity of 131I for
treatment was based on standard guidelines for adult patients
[34, 35]. Surveillance consisted of physical examination and
laboratory studies including thyroid stimulating hormone
(TSH), triiodothyronine, and free thyroxine with the addi-
tion of thyroglobulin levels in the latter years of the study.
Statistical analysis
Clinical and pathological outcomes and BRAF mutational
status were analyzed for significant associations. P < 0.05
was considered statistically significant and all P values were
two-tailed. T tests were used for comparison of data with
continuous variables, while Chi-squared tests were used for
dichotomous data. All variables associated with the BRAF
mutation, disease recurrence, or disease-specific survival
(DSS) at the P < 0.05 level were entered into multivariate
logistic regression models for BRAF positivity. To remove
redundancy and improve the predictive value of the multi-
variate analysis, complex variables such as AJCC Stage were
reduced to the variables they comprise, such as histologic
tumor size, extrathyroidal extension, and location of dis-
ease at diagnosis. Kaplan–Meier analysis was also per-
formed to estimate the recurrence-free survival and DSS
probabilities for BRAF mutation positive versus negative
patient groups. Statistical analyses were performed using
SAS, Version 9.2 (SAS Institute, Inc., Cary, NC).
Results
Patient characteristics
A total of 508 patients meeting eligibility criteria with
evaluable tissue underwent BRAF gene analysis. Patient
and tumor characteristics are illustrated in Table 1. Aver-
age age at diagnosis was 45.5  15.1 years (range 5.8–
84.6 years, median 45.1 years) and mean follow-up time
was 9.8 years with a median follow-up time of 8.0 years
(range of 0.1–40.1 years). Pathological findings included
thyroid capsular invasion in 47%, vascular invasion in
15%, microscopic positive margins in 28%, soft tissue
invasion in 30%, and bilateral thyroid involvement in
36%. The average histologic tumor size was 2.0  1.7 cm
at the largest dimension. The majority of patients had dis-
ease limited to the thyroid only (54.8%, 278/507), 42.2%
had disease in the neck nodes and thyroid, 2.8% had dis-
tant metastases to the lung, and 0.2% had disease in the
thyroid and bone metastases.
BRAF analysis
The BRAF mutation was present in 66.9% of patients
(340/508). Mutation status was identified by RFLP, which
displayed two, wild-type DNA bands (120 and 95 bp)
digested by the TspRI restriction enzyme when the BRAF
V600 mutation was absent, and three DNA bands (215,
120, and 95 bp) when the BRAF V600 mutation was pres-
ent (heterozygote). Representative cases are illustrated in
Figure 1. Follow-up time did not differ between BRAF-
positive and BRAF-negative patients (P = 0.507). Initial
RAI dose also did not differ between BRAF-positive and
-negative patients (P = 0.824). The presence of the BRAF
mutation was associated with classic papillary histology
(P = 0.003), capsular invasion (P = 0.001), soft tissue
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invasion (P < 0.001), positive margins after surgery
(P = 0.004), cervical lymph node involvement (P = 0.002),
and tumor location at diagnosis (P = 0.004) (Table 1). On
multivariate analysis, only capsular invasion (HR, 1.7; 95%
CI, 1.1–2.6), classic papillary histology (HR, 1.8; 95% CI
1.1–2.9), and cervical lymph node involvement (HR, 1.7;
95% CI, 1.1–2.7) at the time of diagnosis were indepen-
dently predictive of the BRAF mutation.
Patient outcome
Overall survival for the entire cohort at 10 and 20 years
was 95.4% and 84.5%, respectively. A total of 49 patients
died during the study period and 13 of these deaths
(27%) were due to thyroid cancer. Disease-specific sur-
vival at 10 and 20 years was 97.4% and 96.8%, respec-
tively. Recurrence-free survival (RFS) at 10 and 20 years
was 88.8% and 80.3%, respectively. There was no differ-
ence in the probability of RFS in patients with the BRAF
mutation than in patients without the mutation (Fig. 2).
Similarly, the probability of DSS was not different in
patients with or without the BRAF mutation (Fig. 3).
These findings were consistent with the lack of association
observed between the BRAF mutation and increased risk
of recurrence or cancer-related mortality on univariate
and multivariate analyses.
Table 1. Patient, tumor and treatment characteristics stratified by BRAFV600 mutation.
Characteristic
Number (%) or median
(range) BRAFV600 positive (%) BRAFV600 negative (%) P value
All patients 508 (100) 340 (66.9) 168 (33.1) NA
Gender
Male 125 (24.6) 88 (70.4) 37 (29.6) 0.342
Female 383 (75.4) 252 (65.7) 131 (34.2)
Age at diagnosis (years) 45.1 (5.8–84.6) 45.5 (5.8–81.6) 45.1 (13.9–84.6) 0.679
Race
White 423 (83.3) 285 (67.4) 138 (32.6) 0.714
Black 50 (9.8) 33 (66.0) 17 (34.0)
Asian 25 (4.9) 17 (68.0) 8 (32.0)
Hispanic 10 (2.0) 5 (50.0) 5 (50.0)
Histology
Classic papillary 377 (74.2) 266 (70.6) 111 (29.4) 0.003
Follicular variant 131 (25.8) 74 (56.5) 57 (43.5)
Pathological features
Thyroid capsule invasion 240 (47.3) 181 (59.2) 59 (30.5) 0.001
Soft tissue invasion 151 (29.8) 118 (78.2) 33 (21.9) <0.001
Vascular invasion 74 (14.6) 54 (73.0) 20 (27.0) 0.223
Positive margins 144 (28.4) 110 (76.4) 34 (23.6) 0.004
Tumor size (cm) 1.5 (0.1–13.0) 1.5 (0.1–9.2) 1.5 (0.2–13.0) 0.600
Multifocal 233 (46.0) 153 (65.7) 80 (34.3) 0.597
Cervical LN involvement 228 (45.0) 169 (74.1) 59 (25.9) 0.002
Extent of disease 0.004
Thyroid only 278 (54.8) 170 (61.2) 108 (38.9) 0.002
Thyroid and cervical LN 214 (42.2) 161 (75.2) 53 (24.8) <0.001
Lung metastases 14 (2.8) 7 (50.0) 7 (50.0) 0.172
Bone metastases 1 (0.2) 1 (100) 0 (0) 0.482
AJCC tumor stage
T1 217 (39.8) 139 (63.4) 78 (36.6) 0.037
T2 126 (26.3) 77 (58.0) 49 (42.0)
T3 55 (12.1) 42 (69.6) 13 (30.4)
T4 106 (21.9) 80 (71.2) 26 (28.8)
AJCC nodal stage
N0 279 (57.5) 172 (58.1) 107 (41.9) 0.015
N1a 164 (30.8) 119 (72.2) 45 (27.8)
N1b 62 (11.7) 48 (76.1) 14 (23.9)
Initial I-131 dose (mCi) 150 (0–980) 150 (0–980) 150 (0–950) 0.498
Total I-131 dose (mCi) 150 (0–980) 150 (0–980) 150 (0–950) 0.681
Follow-up time (years) 8.0 (0.1–40.1) 8.0 (0.1–30.2) 7.8 (1.1–40.1) 0.306
LN, lymph node; AJCC, American Joint Committee on Cancer.
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Numerous known correlates of high-risk disease were
associated with increased risk for recurrence and disease-spe-
cific mortality (Table 2). For recurrence and cancer-specific
death, significantly associated pathological features included
capsular invasion, vascular invasion, soft tissue invasion,
positive surgical margins, and histologic tumor size
(Table 2). Tumor involvement of the cervical lymph nodes
or lung at diagnosis was also associated with increased recur-
rence and mortality, whereas tumor confined to the thyroid
was negatively correlated with both outcomes (Table 2).
Male gender was associated with disease recurrence
(P = 0.009) only, while increasing age was associated with
increased risk of cancer-specific death (P < 0.001).
On multivariate analysis, only histologic tumor size
(HR, 1.3; 95% CI 1.2–1.5), capsular invasion (HR, 2.2;
95% CI 1.1–4.4), vascular invasion (HR, 2.1; 95% CI 1.2–
3.8), classic papillary histology (HR, 2.6; 95% CI 1.1–6.4),
and cervical lymph node involvement (HR, 2.8; 95% CI
1.4–5.4) remained independent risk factors for recurrence.
Independent predictors of disease-specific mortality
included vascular invasion (HR, 3.8; 95% CI 1.05–13.55),
positive surgical margins (HR, 8.2; 95% CI 1.8–37.3), and
increased age at diagnosis (HR, 1.1; 95% CI 1.1–1.2).
Discussion
This study sought to clarify the relationship between the
BRAF mutation and long-term outcome in PTC. Previ-
ously, the BRAF mutation has been reported to indicate a
poorer prognosis in PTC although there have been signif-
icant inconsistencies between various studies [17–24]. In
our analysis, we found a consistent lack of relationship
between the BRAF mutation and either disease recurrence
or disease-specific mortality. This was uniformly observed
across univariate, multivariate, and Kaplan–Meier analy-
ses.
The method we used to test for the V600E mutation
was restriction fragment polymorphism analysis (RFLP).
It was the method used by some large reference labs until
early 2009 and thus has demonstrated clinical accuracy. It
is noteworthy that during most of the time frame covered
by the studies in our paper discussing correlations in out-
come with BRAF mutations had a physician outside of an
academic medical center ordered mutational analysis, it
would likely have been done by RFLP analysis. Testing
has shifted from RFLP to direct DNA sequence analysis
in large reference laboratories because a test kit that has
FDA approval has become available, not because of accu-
racy concerns with RFLP.
A majority of the patients in our cohort (67%) had the
BRAF mutation, which is consistent with populations
represented in the literature [7–9]. It has been suggested
that this high prevalence of the BRAF mutation in PTC
suggests an important role for the mutation in PTC-related
morbidity and mortality [18]. However, we propose the
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Figure 1. BRAFV600 evaluation. Representative analysis of FFPE
thyroid tissue specimens. DNA from four samples was amplified by
PCR and submitted to RFLP by incubation with the restriction enzyme
TspRI. Two samples displayed mutated (V600E, V600K, etc.) digestion
pattern, with three fragments of 215 bp (undigested, mutated allele),
120 and 95 bp. Two samples displayed the wild-type (Wt) digestion
pattern, showing two fragments of 120 and 95 bp, respectively. M,
molecular marker; //, empty lane.
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mortality in PTC (10% and 5% of patients, respectively)
and the contrastingly high prevalence of the mutation
(70%, on average, in the literature), an absence of a link
between the BRAF mutation and these negative events
seems logical [2, 7–9]. Importantly, the lack of prognostic
value of the BRAF mutation observed in this study is not
attributable to difference in follow-up time or treatment
between BRAF-positive and -negative patient groups
(Table 1).
We also evaluated the association between known clini-
copathologic factors of poor prognosis and the BRAF
mutation. While multiple poor prognostic factors corre-
lated with BRAF mutations on univariate analysis
(Table 1), only capsular invasion, cervical lymph node
involvement, and classic papillary histology remained
independently predictive of the BRAF mutation on multi-
variate analysis [13–16]. All three have previously been
described to predict for BRAF mutations [13–16, 19]. The
significant association between the BRAF mutation and
the classic papillary histologic sub-type of PTC (the most
common sub-type) in this analysis, in comparison to the
follicular variant sub-type, is a well-documented relation-
ship [13, 20, 21, 24, 26, 36].
Compared to studies that used univariate analysis, our
multivariate analysis revealed few risk factors that corre-
lated with the BRAF mutation. A recent publication detail-
ing the University of California, San Francisco experience
has called into question the relationship between the BRAF
mutation and poor clinicopathologic factors. In the
analysis of a cohort of 429 patients, Gouveia, et al. found a
minimal association between the mutation and negative
prognostic indicators on multivariate analysis [24, 37].
In addition, we analyzed the associations between com-
mon clinicopathologic features, RFS, and DSS. The strong-
est predictor of increased risk on multivariate analysis for
recurrence was cervical lymph node involvement, followed
by classic papillary histology, capsular invasion, vascular
invasion, and then histologic tumor size. These are well-
documented risk factors and are components of the current
AJCC staging system [9, 13, 19, 24, 34, 35]. Our results sug-
gest that the current means of initial prognostication for
PTC already accounts for the greatest established predictors
of recurrence. For cancer-specific death, the strongest pre-
dictors were older age at diagnosis, positive surgical mar-
gins, and vascular invasion [9, 17–19, 22]. Advanced age
and positive margins were associated with an eightfold
increase of disease-specific mortality.
The greatest strengths of this analysis are its extensive
follow-up time (mean 9.8 years, median 8.0 years, range
40.1 years) and large cohort. The bulk of recurrences and
disease-specific deaths in our cohort occurred at least
2.5 years (and up to 23.5 years) after diagnosis. These
events were also rare, occurring in only 11.0% and 2.6% of
patients, respectively. If the range of follow-up time of our
study had been limited to 67 months, the follow-up range
in one of the most-cited meta-analyses, we would have
failed to capture 25% of disease recurrences and 54% of
the cancer-specific deaths in our cohort [19]. Thus, the
Table 2. Univariate analyses of clinicopathologic features for association with disease recurrence and cause-specific survival.
Risk of recurrence Risk of death




(95% CI) P value
Hazard ratio
for recurrence
(95% CI) P value
Hazard ratio
for disease-specific
mortality (95% CI) P value
Hazard ratio
for disease-specific
mortality (95% CI) P value
BRAF mutation 1.3 (0.7–2.3) 0.376 Eliminated NS 2.9 (0.6–13.1) 0.165 Eliminated NS
Age at diagnosis 1.0 (0.98–1.01) 0.653 Eliminated NS 1.1 (1.0–1.1) <0.001 8.2 (1.8–37.3) <0.001
Multifocal disease 1.5 (0.9–2.6) 0.112 Eliminated NS 3.4 (0.9–12.6) 0.066 Eliminated NS
Classic papillary histology 2.7 (1.1–6.2) 0.024 2.6 (1.1–6.4) 0.035 3.5 (0.5–27.0) 0.230 Eliminated NS
Male gender 2.0 (1.2–3.5) 0.009 Eliminated NS 2.6 (0.9–7.7) 0.088 Eliminated NS
Disease location
Thyroid only 0.2 (0.1–0.4) <0.001 0.1 (0.01–0.6) 0.013
Nodal involvement 2.8 (1.6–5.0) <0.001 Eliminated NS 2.0 (0.6–6.0) 0.235 Eliminated NS
Lungs 7.8 (3.3–18.3) <0.001 22.5 (6.7–75.1) <0.001
Bone 0 (0) 0.986 0 (0) 0.993
Soft tissue invasion 3.5 (2.1–6.0) <0.001 Eliminated NS 5.0 (1.5–16.6) 0.009 Eliminated NS
Positive margins 2.9 (1.8–4.6) <0.001 Eliminated NS 7.5 (2.0–27.8) 0.002 8.2 (1.8–37.3) 0.006
Thyroid capsule invasion 4.6 (2.4–8.6) <0.001 2.2 (1.1–4.4) 0.028 13.0 (1.7–100.7) 0.014 Eliminated NS
Vascular invasion 3.6 (2.0–6.2) <0.001 2.1 (1.2–3.8) 0.01 3.8 (1.2–12.0) 0.023 3.7 (1.05–13.6) 0.042
Cervical LN involvement 4.6 (2.5–8.8) <0.001 2.8 (1.4–5.4) 0.004 13.7 (1.8–105.6) 0.012 Eliminated NS
Histologic tumor size 1.3 (1.2–1.4) <0.001 1.2 (1.2–1.5) <0.001 1.4 (1.2–1.6) <0.001 Eliminated NS
LN, lymph node.
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importance of having a large cohort and extensive follow-
up data in this study cannot be emphasized strongly
enough. One weakness of this analysis is its retrospective
nature. However, all patients were treated homogeneously,
following guidelines at a single, academic institution.
Our data confirm the high incidence of the BRAF
mutation in our population. Approximately 70% of
patients will have the mutation. Although the presence of
the mutation is not independently predictive of poor out-
come, a significant percent of BRAF-positive patients will
develop recurrence and metastatic disease. Therefore,
treatments guided by presence of the mutation are war-
ranted. Such therapies might include increased cervical
nodal dissection and use of BRAF inhibitors. Both in this
patient cohort and in previous reports, preoperative BRAF
mutation status in cytology specimens has correlated with
lymph node status, and some suggest it could guide the
extent of node removal during surgery [38]. We propose
that the clear role for BRAF testing lies in patients who
suffer multiple recurrences or develop radioactive iodine
(RAI) resistance. Approximately two-thirds of those
patients (those with the BRAF mutation) might benefit
from targeted therapy with BRAF inhibitors, which have
been developed for treatment of metastatic melanoma.
BRAF inhibitors have shown promising results against
thyroid cancer cells with BRAF mutations in vivo [39].
Additionally, preliminary results from the phase III DECI-
SION trial demonstrate that Sorafenib, a non-specific
active BRAF inhibitor, significantly improves PFS com-
pared to placebo in patients with progressive RAI-refrac-
tory differentiated thyroid carcinoma [40]. However, the
DECISION trial included both BRAF-positive and BRAF-
negative patients, a factor that is likely to significantly
reduce the observed efficacy of BRAF inhibitors in this
population. A randomized trial to evaluate the safety and
efficacy of BRAF inhibitors to improve progression-free
survival in progressive RAI-refractory PTC patients, with
stratification of patients into sub-groups on the basis of
BRAF mutational status is warranted.
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